icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
11 Feb, 2021 15:49

African Union not ‘walking away’ from AstraZeneca’s Covid-19 vaccine, despite efficacy worries against South Africa variant

African Union not ‘walking away’ from AstraZeneca’s Covid-19 vaccine, despite efficacy worries against South Africa variant

Health officials in the African Union (AU) have said states without the South African strain of Covid-19 should use AstraZeneca’s vaccine, insisting the bloc was not abandoning the jab, in spite on concerns about its efficacy.

A supply of 100 million AstraZeneca’s vaccine, set to be received this year by the AU, will still be used and distributed among countries across the continent, John Nkengasong, director of the Africa Centres for Disease Control and Prevention, said during a virtual press conference on Thursday.

For now, our strategy is not to throw away our 100 million doses, but rather to target countries that, as we indicated, have not reported cases of that specific variant.

“You still have an extensive number of countries that can benefit from those vaccines, so we will not be walking away from AstraZeneca vaccines at all,” the official added, revealing that only six countries on the continent other than South Africa had reported cases of the extra-contagious variant of the virus.

Also on rt.com South Africa considers selling or swapping its AstraZeneca vaccine stash over efficacy concerns

South Africa halted its mass vaccination campaign using the AstraZeneca solution over the weekend, after a scientific study raised concerns over its effectiveness. The research by South Africa’s University of the Witwatersrand and the UK’s Oxford University showed the AstraZeneca jab fared poorly against the more contagious variant. However, the research is not peer-reviewed yet and has been criticized by some experts over its limited scope.

The vaccination campaign stalled just a few days after its launch. South Africa received its first 100-million-dose batch of AstraZeneca jabs, manufactured by the Serum Institute of India, only last week. While the efficacy of the vaccine against the local strain is now under scrutiny, the country is set to receive a further 500,000 doses in the coming weeks.

The fate of the South African AstraZeneca stockpile remains unclear, yet the country’s authorities have already expressed a readiness to either sell it off or swap it for vaccines produced by other manufacturers. South Africa said it has been preparing to begin small-scale pilot rollouts of coronavirus shots by Johnson & Johnson and Pfizer.

Also on rt.com South Africa to give up to 500,000 health workers Johnson & Johnson Covid jab amid AstraZeneca efficacy concerns

So far, South Africa has recorded the highest number of Covid-19 infections and deaths of all African nations. Its case tally is nearing the 1.5 million mark, and its death toll is hovering at around 47,000.

The African Union has agreed deals with AstraZeneca, Pfizer, and Johnson & Johnson to supply some 670 million doses of their vaccines to the bloc. It also expects to receive some 600 million doses this year via the World Health Organisation’s Covax scheme.

Think your friends would be interested? Share this story!